LT2644205T - Nutaikymas į abcb5 vėžio terapijai - Google Patents

Nutaikymas į abcb5 vėžio terapijai

Info

Publication number
LT2644205T
LT2644205T LTEP13163810.8T LT13163810T LT2644205T LT 2644205 T LT2644205 T LT 2644205T LT 13163810 T LT13163810 T LT 13163810T LT 2644205 T LT2644205 T LT 2644205T
Authority
LT
Lithuania
Prior art keywords
cancer therapy
abcb5
targeting
targeting abcb5
cancer
Prior art date
Application number
LTEP13163810.8T
Other languages
English (en)
Inventor
Markus H. Frank
Natasha Y. Frank
Mohamed H. Sayegh
Original Assignee
The Brigham And Women`S Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women`S Hospital, Inc. filed Critical The Brigham And Women`S Hospital, Inc.
Publication of LT2644205T publication Critical patent/LT2644205T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
LTEP13163810.8T 2007-04-12 2008-04-11 Nutaikymas į abcb5 vėžio terapijai LT2644205T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92312807P 2007-04-12 2007-04-12
US705907P 2007-12-11 2007-12-11

Publications (1)

Publication Number Publication Date
LT2644205T true LT2644205T (lt) 2018-12-10

Family

ID=39661432

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13163810.8T LT2644205T (lt) 2007-04-12 2008-04-11 Nutaikymas į abcb5 vėžio terapijai

Country Status (15)

Country Link
US (4) US7928202B2 (lt)
EP (3) EP3431103B1 (lt)
JP (4) JP5889527B2 (lt)
AU (1) AU2008239633B2 (lt)
CA (1) CA2718573C (lt)
CY (2) CY1116823T1 (lt)
DK (2) DK2644205T3 (lt)
ES (2) ES2547016T3 (lt)
HR (2) HRP20150934T1 (lt)
HU (2) HUE039385T2 (lt)
LT (1) LT2644205T (lt)
PL (2) PL2644205T3 (lt)
PT (2) PT2155248E (lt)
SI (2) SI2644205T1 (lt)
WO (1) WO2008127656A1 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140868D1 (de) 2000-06-05 2010-02-04 Brigham & Womens Hospital Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
ES2511791T3 (es) 2006-05-31 2014-10-23 Children's Medical Center Corporation Células madre mesenquimales positivas para ABCB5 como moduladoras de inmunidad
CA2718573C (en) * 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
CA2743464A1 (en) 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
EP2569011A4 (en) * 2010-05-14 2013-06-12 Univ Hong Kong ANTIBODIES AGAINST GEP AND APPLICATIONS THEREOF
DK2964238T3 (da) 2013-02-19 2021-03-22 Childrens Medical Center Abcb5(+) stem cells for treating ocular disease
US11446331B2 (en) 2013-05-10 2022-09-20 The Brigham And Women's Hospital, Inc. Wound healing and tissue engineering
US9177410B2 (en) 2013-08-09 2015-11-03 Ayla Mandel System and method for creating avatars or animated sequences using human body features extracted from a still image
US20180134771A1 (en) * 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
MX2020011297A (es) * 2018-04-25 2020-11-18 Childrens Medical Center Ligandos y substratos de abcb5.
US20230136997A1 (en) * 2020-04-15 2023-05-04 Children's Medical Center Corporation Targeting abcb5 in glioblastoma multiforme
JP2023524102A (ja) * 2020-04-30 2023-06-08 ザ チルドレンズ メディカル センター コーポレーション Ａｂｃｂ５に特異的な抗体およびその使用
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
GB2047543B (en) 1978-12-06 1983-04-20 Svedman Paul Device for treating tissues for example skin
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
AT379688B (de) 1982-11-22 1986-02-10 List Hans Sensorelement zur bestimmung des o2-gehaltes einer probe
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0174810B1 (en) 1984-09-10 1993-07-21 HSC Research Development Corporation Multidrug resistance in mammalian cell lines and isolation of determinant glycoprotein dna
US4837306A (en) 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
GB8509978D0 (en) 1985-04-18 1985-05-30 Juhasz L Wound dressings
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5399483A (en) 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6436078B1 (en) 1994-12-06 2002-08-20 Pal Svedman Transdermal perfusion of fluids
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB2272645B8 (en) 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
JPH09507487A (ja) 1994-01-05 1997-07-29 アーキュール，インコーポレーテッド 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造
GB9403135D0 (en) 1994-02-18 1994-04-06 Univ Glasgow Wound healing device
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU3277097A (en) * 1996-06-28 1998-01-21 Matsushita Electric Works Ltd. Modification apparatus
US5904659A (en) 1997-02-14 1999-05-18 Exogen, Inc. Ultrasonic treatment for wounds
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE19722075C1 (de) 1997-05-27 1998-10-01 Wilhelm Dr Med Fleischmann Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
US6071267A (en) 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
GB9808836D0 (en) 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
JP4220058B2 (ja) 1998-06-30 2009-02-04 浜松ホトニクス株式会社 半導体位置検出器
US6479072B1 (en) 1999-02-11 2002-11-12 The General Hospital Corporation Microfabricated membranes and matrices
US6277574B1 (en) 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney
CA2390131C (en) 1999-11-29 2009-06-23 Hill-Rom Services, Inc. Wound treatment apparatus
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
DE60140868D1 (de) 2000-06-05 2010-02-04 Brigham & Womens Hospital Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
AU2001268328A1 (en) * 2000-06-12 2001-12-24 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
AU7142201A (en) 2000-06-22 2002-01-02 Genentech Inc Agonist anti-trk-c monoclonal antibodies
EP1322936A2 (en) 2000-10-03 2003-07-02 California Institute Of Technology Microfluidic devices and methods of use
EP1412387A2 (en) 2000-10-27 2004-04-28 Incyte Genomics, Inc. Transporters and ion channels
US6685681B2 (en) 2000-11-29 2004-02-03 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US8015677B2 (en) 2000-12-01 2011-09-13 Aard-Balm Limited Embalming fluid
US6767194B2 (en) 2001-01-08 2004-07-27 President And Fellows Of Harvard College Valves and pumps for microfluidic systems and method for making microfluidic systems
US6899873B2 (en) 2001-02-02 2005-05-31 The Regents Of The University Of Michigan Method of forming micro-tubular polymeric materials
US6695824B2 (en) 2001-04-16 2004-02-24 The United States Of America As Represented By The Secretary Of The Army Wound dressing system
US7723560B2 (en) 2001-12-26 2010-05-25 Lockwood Jeffrey S Wound vacuum therapy dressing kit
EP2623138B1 (en) 2001-12-26 2020-08-05 KCI Licensing, Inc. Vented vacuum bandage with irrigation for wound healing and method
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
AU2003285878B2 (en) 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
WO2005054445A1 (en) 2003-11-24 2005-06-16 The Rockefeller University A method for isolating a self-renewing, multipotent slow-cycling cell
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
US7364592B2 (en) 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
CA3218940A1 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
JP2008546387A (ja) 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2511791T3 (es) 2006-05-31 2014-10-23 Children's Medical Center Corporation Células madre mesenquimales positivas para ABCB5 como moduladoras de inmunidad
US20080118432A1 (en) 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
CA2718573C (en) * 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
CA2743464A1 (en) 2008-11-14 2010-05-20 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
DK2964238T3 (da) 2013-02-19 2021-03-22 Childrens Medical Center Abcb5(+) stem cells for treating ocular disease
US11446331B2 (en) 2013-05-10 2022-09-20 The Brigham And Women's Hospital, Inc. Wound healing and tissue engineering

Also Published As

Publication number Publication date
US20160136297A1 (en) 2016-05-19
US20140302031A1 (en) 2014-10-09
DK2155248T3 (en) 2015-09-14
SI2644205T1 (sl) 2018-11-30
AU2008239633B2 (en) 2014-05-29
JP5889527B2 (ja) 2016-03-22
DK2644205T3 (en) 2018-09-24
EP3431103B1 (en) 2021-07-28
JP2016188248A (ja) 2016-11-04
CY1121046T1 (el) 2019-12-11
US9266946B2 (en) 2016-02-23
PT2644205T (pt) 2018-10-19
EP2644205B1 (en) 2018-06-13
CY1116823T1 (el) 2017-03-15
EP3431103A1 (en) 2019-01-23
US20110165149A1 (en) 2011-07-07
JP2014133770A (ja) 2014-07-24
JP6530044B2 (ja) 2019-06-12
CA2718573C (en) 2020-07-14
SI2155248T1 (sl) 2015-12-31
JP6268237B2 (ja) 2018-01-24
PL2644205T3 (pl) 2018-11-30
EP2155248A1 (en) 2010-02-24
JP2018052979A (ja) 2018-04-05
US7928202B2 (en) 2011-04-19
US20090117117A1 (en) 2009-05-07
EP2644205A1 (en) 2013-10-02
PL2155248T3 (pl) 2015-12-31
US8697072B2 (en) 2014-04-15
EP2155248B1 (en) 2015-06-10
ES2687270T3 (es) 2018-10-24
AU2008239633A1 (en) 2008-10-23
HUE027593T2 (en) 2016-11-28
HRP20150934T1 (hr) 2015-11-06
HUE039385T2 (hu) 2018-12-28
PT2155248E (pt) 2015-10-23
JP2010534191A (ja) 2010-11-04
US9855342B2 (en) 2018-01-02
ES2547016T3 (es) 2015-09-30
WO2008127656A1 (en) 2008-10-23
HRP20181385T1 (hr) 2018-10-19
CA2718573A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
HRP20181385T1 (hr) Ciljanje abcb5 za terapiju raka
ZA201004403B (en) Therapeutic cancer treatments
EP2318040A4 (en) THERAPY TREATED ON CANCER STAMPS
HK1185414A1 (en) Drug selection for breast cancer therapy using antibody-based arrays
EP2303337A4 (en) MEDICAMENT-LIGAND SMALL MOLECULE CONJUGATES FOR TARGETED CANCER TREATMENT
HK1201724A1 (en) Cancer stem cell-targeted cancer therapy
EP2127671A4 (en) THERAPEUTIC AGENT AGAINST CANCER
IL215764A0 (en) Adjuvant cancer therapy
IL199992A0 (en) Combination therapy
HK1147684A1 (en) Targeted radiotherapy
GB0719518D0 (en) Therapy
EP2211863A4 (en) COMBINATION THERAPY
GB0707556D0 (en) Treatment for cancer
EP2099303A4 (en) THERAPEUTIC COMPOSITIONS ON TETRAHYDROISOCHINOLINE BASE FOR CANCER THERAPY
GB0700284D0 (en) Combination therapy
GB0809046D0 (en) Cancer treatment
PT2305654E (pt) Agente terapêutico para a dor relacionada com o cancro
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0706538D0 (en) Cancer therapeutic
IL210247A0 (en) Ccl20 - specific antibodies for cancer therapy
GB0606702D0 (en) Cancer therapeutic
GB0612259D0 (en) Cancer therapeutic
AU2008902090A0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy